Several CHK1 inhibitors have been developed and are currently in various stages of clinical trials. These include compounds such as prexasertib, SRA737, and LY2606368. These inhibitors are often used in combination with other therapies, such as chemotherapy or radiation, to enhance their efficacy by increasing DNA damage in cancer cells beyond repairable levels.
